{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:13:09Z","timestamp":1779185589557,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04079-6","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T15:02:25Z","timestamp":1729350145000},"page":"1323-1332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunohistochemical expression of ephrin receptors in neuroendocrine neoplasms: a case-series of gastroenteropancreatic neuroendocrine neoplasms and a systematic review of the literature"],"prefix":"10.1007","volume":"87","author":[{"given":"Krystallenia I.","family":"Alexandraki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadni","family":"Spyroglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Karapanagioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Antonopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irini","family":"Theohari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odysseas","family":"Violetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios C.","family":"Sotiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatios","family":"Theocharis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"4079_CR1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","volume":"39","author":"DS Klimstra","year":"2010","unstructured":"D.S. Klimstra, I.R. Modlin, D. Coppola, R.V. Lloyd, S. Suster, The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39, 707\u2013712 (2010)","journal-title":"Pancreas"},{"key":"4079_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coemr.2021.05.002","volume":"19","author":"A Spyroglou","year":"2021","unstructured":"A. Spyroglou, K. Bramis, K.I. Alexandraki, Neuroendocrine neoplasms: evolving and future treatments. Current Opinion in Endocrine and Metabolic Research 19, 15\u201321 (2021)","journal-title":"Current Opinion in Endocrine and Metabolic Research"},{"key":"4079_CR3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/jpm9040048","volume":"9","author":"KI Alexandraki","year":"2019","unstructured":"K.I. Alexandraki, E. Papadimitriou, V. Mavroeidi, G. Kyriakopoulos, A. Xydakis, et al., Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues. Journal of Personalized Medicine 9, 48 (2019).","journal-title":"Journal of Personalized Medicine"},{"key":"4079_CR4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/ph17030354","volume":"17","author":"A Bracigliano","year":"2024","unstructured":"A. Bracigliano, A.L. Marretta, L.P. Guerrera, R. Simioli, O. Clemente et al. The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives. Pharmaceuticals (Basel) 17, 354 (2024)","journal-title":"Pharmaceuticals (Basel)"},{"key":"4079_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/a-1023-4214","volume":"52","author":"M Tsoli","year":"2020","unstructured":"M. Tsoli, K.I. Alexandraki, M.E. Spei, G.A. Kaltsas, K. Daskalakis,, Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and\/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Hormone and Metabolic Research 52, 25\u201331 (2020).","journal-title":"Hormone and Metabolic Research"},{"key":"4079_CR6","volume":"23","author":"S Das","year":"2021","unstructured":"S. Das, A. Dasari,, Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. Current Oncology Reports 23, 43 2021).","journal-title":"Current Oncology Reports"},{"key":"4079_CR7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/path.1937","volume":"208","author":"J Zhang","year":"2006","unstructured":"J. Zhang, S. Hughes,, Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. Journal of Pathology 208, 453\u2013461 (2006).","journal-title":"Journal of Pathology"},{"key":"4079_CR8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.17925\/EE.2023.19.2.12","volume":"19","author":"E Papadimitriou","year":"2023","unstructured":"E. Papadimitriou, E. Chatzellis, A. Dimitriadi, G.A. Kaltsas, S. Theocharis et al. Prognostic Biomarkers in Pituitary Tumours: A Systematic Review. touchREV Endocrinol 19, 42\u201353 (2023)","journal-title":"touchREV Endocrinol"},{"key":"4079_CR9","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1039\/D0OB00391C","volume":"18","author":"M Pretze","year":"2020","unstructured":"M. Pretze, C. Neuber, E. Kinski, B. Belter, M. Kockerling et al. Synthesis, radiolabelling and initial biological characterisation of (18)F-labelled xanthine derivatives for PET imaging of Eph receptors. Organic and Biomolecular Chemistry 18, 3104\u20133116 (2020)","journal-title":"Organic and Biomolecular Chemistry"},{"key":"4079_CR10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.bjc.6603642","volume":"96","author":"SR Kumar","year":"2007","unstructured":"S.R. Kumar, R. Masood, W.A. Spannuth, J. Singh, J. Scehnet et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. British Journal of Cancer 96, 1083\u20131091 (2007)","journal-title":"British Journal of Cancer"},{"key":"4079_CR11","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1541-7786.MCR-08-0244","volume":"6","author":"J Wykosky","year":"2008","unstructured":"J. Wykosky, W. Debinski, The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Molecular Cancer Research 6, 1795\u20131806 (2008)","journal-title":"Molecular Cancer Research"},{"key":"4079_CR12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nature03626","volume":"435","author":"E Batlle","year":"2005","unstructured":"E. Batlle, J. Bacani, H. Begthel, S. Jonkheer, A. Gregorieff et al. EphB receptor activity suppresses colorectal cancer progression. Nature 435, 1126\u20131130 (2005)","journal-title":"Nature"},{"key":"4079_CR13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"G. Rindi, O. Mete, S. Uccella, O. Basturk, S. La Rosa et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 33, 115\u2013154 (2022)","journal-title":"Endocrine Pathology"},{"key":"4079_CR14","doi-asserted-by":"crossref","first-page":"BR257","DOI":"10.12659\/MSM.881929","volume":"17","author":"NP Karidis","year":"2011","unstructured":"N.P. Karidis, C. Giaginis, G. Tsourouflis, P. Alexandrou, I. Delladetsima et al. Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Medical Science Monitor 17, BR257\u2013BR265 (2011)","journal-title":"Medical Science Monitor"},{"key":"4079_CR15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/diagnostics12020366","volume":"12","author":"I Nikas","year":"2022","unstructured":"I. Nikas, C. Giaginis, K. Petrouska, P. Alexandrou, A. Michail et al. EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer. Diagnostics (Basel) 12, 366 (2022)","journal-title":"Diagnostics (Basel)"},{"key":"4079_CR16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41374-018-0057-0","volume":"98","author":"DK Meyerholz","year":"2018","unstructured":"D.K. Meyerholz, A.P. Beck, Principles and approaches for reproducible scoring of tissue stains in research. Laboratory Investigation 98, 844\u2013855 (2018)","journal-title":"Laboratory Investigation"},{"key":"4079_CR17","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102841","volume":"54","author":"E Armeni","year":"2023","unstructured":"E. Armeni, K.I. Alexandraki, F. Roncaroli, A.B. Grossman, Primary Pituitary Carcinoids Do Not Exist: A Reappraisal in the Era of Pituitary Neuroendocrine Tumours. Archives of Medical Research 54, 102841 (2023)","journal-title":"Archives of Medical Research"},{"key":"4079_CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11033-023-09186-7","volume":"51","author":"H Rubinfeld","year":"2024","unstructured":"H. Rubinfeld, Z.R. Cohen, U. Bendavid, S. Fichman-Horn, A. Levy-Barda et al. Erythropoietin-producing hepatocellular receptor B6 is highly expressed in non-functioning pituitary neuroendocrine tumors and its expression correlates with tumor size. Molecular Biology Reports 51, 297 (2024)","journal-title":"Molecular Biology Reports"},{"key":"4079_CR19","doi-asserted-by":"publisher","first-page":"EP751","DOI":"10.1530\/endoabs81EP751","volume":"81","author":"E Papadimitriou","year":"2022","unstructured":"E. Papadimitriou, G. Kyriakopoulos, K. Barkas, I. Gkalonakis, P. Pantoula et al. Immunohistochemichal expression of ephrin receptor (EPH)-A4, -A5, -B2 and -B5in pituitary lesions. Endocrine Abstracts 81, EP751 (2022). https:\/\/doi.org\/10.1530\/endoabs81EP751","journal-title":"Endocrine Abstracts"},{"key":"4079_CR20","volume":"69","author":"X Gao","year":"2024","unstructured":"X. Gao, R. Zhang, Y. He, X. Wang, W. Bao et al. EphB3 protein is a potential ancillary diagnostic biomarker for thyroid cancers. Annals Diagnostic Pathology 69, 152262 (2024)","journal-title":"Annals Diagnostic Pathology"},{"key":"4079_CR21","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-023-01598-3","volume":"15","author":"P Chatzikyriakou","year":"2023","unstructured":"P. Chatzikyriakou, D. Brempou, M. Quinn, L. Fishbein, R. Noberini et al. A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide. Clinical Epigenetics 15, 196 (2023)","journal-title":"Clinical Epigenetics"},{"key":"4079_CR22","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/15353702231199475","volume":"248","author":"Y Lv","year":"2023","unstructured":"Y. Lv, G. Gu, R. Zeng, Z. Liu, J. Wu et al. Proteomics analysis of carotid body tumor revealed potential mechanisms and molecular differences among Shamblin classifications. Experimental Biology and Medicine (Maywood) 248, 1785\u20131798 (2023)","journal-title":"Experimental Biology and Medicine (Maywood)"},{"key":"4079_CR23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40618-021-01729-8","volume":"45","author":"S Batchu","year":"2022","unstructured":"S. Batchu, A. Hakim, O.S. Henry, J. Madzo, U. Atabek et al. Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes. Journal of Endocrinology Investigation 45, 989\u2013998 (2022)","journal-title":"Journal of Endocrinology Investigation"},{"key":"4079_CR24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.bbrc.2019.09.076","volume":"519","author":"H Ishigaki","year":"2019","unstructured":"H. Ishigaki, T. Minami, O. Morimura, H. Kitai, D. Horio et al. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest. Biochemical Biophysical Research Communications 519, 846\u2013853 (2019)","journal-title":"Biochemical Biophysical Research Communications"},{"key":"4079_CR25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2018.07.030","volume":"434","author":"I Nikas","year":"2018","unstructured":"I. Nikas, H.S. Ryu, S. Theocharis, Viewing the Eph receptors with a focus on breast cancer heterogeneity. Cancer Letters 434, 160\u2013171 (2018)","journal-title":"Cancer Letters"},{"key":"4079_CR26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tcb.2007.03.004","volume":"17","author":"J Egea","year":"2007","unstructured":"J. Egea, R. Klein, Bidirectional Eph-ephrin signaling during axon guidance. Trends in Cell Biology 17, 230\u2013238 (2007)","journal-title":"Trends in Cell Biology"},{"key":"4079_CR27","first-page":"243","volume":"1835","author":"JE Lisle","year":"2013","unstructured":"J.E. Lisle, I. Mertens-Walker, R. Rutkowski, A.C. Herington, S.A. Stephenson, Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer. Biochimica et Biophysica Acta 1835, 243\u2013257 (2013)","journal-title":"Biochimica et Biophysica Acta"},{"key":"4079_CR28","volume":"51","author":"Y Li","year":"2024","unstructured":"Y. Li, H. Fei, Z. Xiao, X. Lu, H. Zhang et al. Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity. Clinical and Experimental Pharmacology Physiology 51, e13902 (2024)","journal-title":"Clinical and Experimental Pharmacology Physiology"},{"key":"4079_CR29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"EB Pasquale","year":"2010","unstructured":"E.B. Pasquale, Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nature Review Cancer 10, 165\u2013180 (2010)","journal-title":"Nature Review Cancer"},{"key":"4079_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/modpathol.2008.188","volume":"22","author":"Y Dong","year":"2009","unstructured":"Y. Dong, J. Wang, Z. Sheng, G. Li, H. Ma et al. Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Modern Pathology 22, 151\u2013160 (2009)","journal-title":"Modern Pathology"},{"key":"4079_CR31","first-page":"1211","volume":"36","author":"BO Wu","year":"2016","unstructured":"B.O. Wu, W.G. Jiang, D. Zhou, Y.X. Cui, Knockdown of EPHA1 by CRISPR\/CAS9 Promotes Adhesion and Motility of HRT18 Colorectal Carcinoma Cells. Anticancer Research 36, 1211\u20131219 (2016)","journal-title":"Anticancer Research"},{"key":"4079_CR32","first-page":"4415","volume":"37","author":"Y Cui","year":"2017","unstructured":"Y. Cui, B.O. Wu, V. Flamini, B.A.J. Evans, D. Zhou et al. Knockdown of EPHA1 Using CRISPR\/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells. Anticancer Research 37, 4415\u20134424 (2017)","journal-title":"Anticancer Research"},{"key":"4079_CR33","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/0008-5472.CAN-04-0020","volume":"64","author":"S Ashida","year":"2004","unstructured":"S. Ashida, H. Nakagawa, T. Katagiri, M. Furihata, M. Iiizumi et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Research 64, 5963\u20135972 (2004)","journal-title":"Cancer Research"},{"key":"4079_CR34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T","volume":"41","author":"J Walker-Daniels","year":"1999","unstructured":"J. Walker-Daniels, K. Coffman, M. Azimi, J.S. Rhim, D.G. Bostwick et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41, 275\u2013280 (1999)","journal-title":"Prostate"},{"key":"4079_CR35","first-page":"11737","volume":"10","author":"S Zhou","year":"2017","unstructured":"S. Zhou, L. Wang, S. Guo, Z. Zhang, J. Wang, EphA4 protein promotes invasion in clear cell renal cell carcinomas. International Journal of Clinical Experimental Pathology 10, 11737\u201311742 (2017)","journal-title":"International Journal of Clinical Experimental Pathology"},{"key":"4079_CR36","doi-asserted-by":"crossref","unstructured":"K. Alexandraki, A. Angelousi, G. Boutzios, G. Kyriakopoulos, D. Rontogianni, G. Kaltsas. Management of neuroendocrine tumors of unknown primary. Reviews in Endocrine and Metabolic Disorders 18, 423\u2013431 (2017)","DOI":"10.1007\/s11154-017-9437-9"},{"key":"4079_CR37","doi-asserted-by":"crossref","first-page":"e102262","DOI":"10.1371\/journal.pone.0102262","volume":"9","author":"MI Toma","year":"2014","unstructured":"M.I. Toma, K. Erdmann, M. Diezel, M. Meinhardt, S. Zastrow et al. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PLoS One 9, e102262 (2014)","journal-title":"PLoS One"},{"key":"4079_CR38","doi-asserted-by":"crossref","first-page":"79003","DOI":"10.18632\/oncotarget.20743","volume":"8","author":"KI Alexandraki","year":"2017","unstructured":"K.I. Alexandraki, A. Philippou, G. Boutzios, I. Theohari, M. Koutsilieris et al. IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms. Oncotarget 8, 79003\u201379011 (2017)","journal-title":"Oncotarget"},{"key":"4079_CR39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12020-021-02639-8","volume":"73","author":"A Koumarianou","year":"2021","unstructured":"A. Koumarianou, G.A. Kaltsas, E. Chatzellis, G. Kyriakopoulos, D. Kolomodi et al. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine 73, 232\u2013239 (2021)","journal-title":"Endocrine"},{"key":"4079_CR40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","volume":"99","author":"Q Chang","year":"2008","unstructured":"Q. Chang, C. Jorgensen, T. Pawson, D.W. Hedley, Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. British Journal of Cancer 99, 1074\u20131082 (2008)","journal-title":"British Journal of Cancer"},{"key":"4079_CR41","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1210\/jc.2019-01299","volume":"104","author":"KI Alexandraki","year":"2019","unstructured":"K.I. Alexandraki, G.A. Kaltsas, N. Karavitaki, A.B. Grossman, The Medical Therapy of Craniopharyngiomas: The Way Ahead. Journal of Clinical Endocrinology Metabolism 104, 5751\u20135764 (2019)","journal-title":"Journal of Clinical Endocrinology Metabolism"},{"key":"4079_CR42","doi-asserted-by":"crossref","first-page":"e95723","DOI":"10.1371\/journal.pone.0095723","volume":"9","author":"M Behr","year":"2014","unstructured":"M. Behr, J.K. Kaufmann, P. Ketzer, S. Engelhardt, M. Muck-Hausl et al. Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One 9, e95723 (2014)","journal-title":"PLoS One"},{"key":"4079_CR43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167144","volume":"433","author":"JM Westerfield","year":"2021","unstructured":"J.M. Westerfield, A.R. Sahoo, D.S. Alves, B. Grau, A. Cameron et al. Conformational Clamping by a Membrane Ligand Activates the EphA2 Receptor. Journal of Molecular Biology 433, 167144 (2021)","journal-title":"Journal of Molecular Biology"},{"key":"4079_CR44","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-08-1933","volume":"68","author":"D Jackson","year":"2008","unstructured":"D. Jackson, J. Gooya, S. Mao, K. Kinneer, L. Xu, et al., A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Research 68, 9367\u20139374 (2008)","journal-title":"Cancer Research"},{"key":"4079_CR45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1593\/neo.81578","volume":"11","author":"EM Bruckheimer","year":"2009","unstructured":"E.M. Bruckheimer, C.A. Fazenbaker, S. Gallagher, K. Mulgrew, S. Fuhrmann et al. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 11, 509\u2013517 (2009)","journal-title":"Neoplasia"},{"key":"4079_CR46","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/jnci\/djp231","volume":"101","author":"JW Lee","year":"2009","unstructured":"J.W. Lee, H.D. Han, M.M. Shahzad, S.W. Kim, L.S. Mangala, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute 101, 1193\u20131205 (2009)","journal-title":"Journal of the National Cancer Institute"},{"key":"4079_CR47","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-007-0503-5","volume":"34","author":"W Cai","year":"2007","unstructured":"W. Cai, A. Ebrahimnejad, K. Chen, Q. Cao, Z.B. Li et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 34, 2024\u20132036 (2007)","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4079_CR48","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1021\/ja801969b","volume":"130","author":"KE Scarberry","year":"2008","unstructured":"K.E. Scarberry, E.B. Dickerson, J.F. McDonald, Z.J. Zhang,, Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. Journal of the American Chemical Society 130, 10258\u201310262 (2008)","journal-title":"Journal of the American Chemical Society"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04079-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04079-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04079-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:20:37Z","timestamp":1740147637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04079-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["4079"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04079-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Laiko University Hospital (1456\/10-12-2012).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}